? Biocon Hits Fresh 52‑Week Peak on NSE
On July 16–18, 2025, Biocon Ltd’s shares climbed to a 52‑week high of around ₹406 on the NSE, gaining nearly 2.5%, thanks to a significant catalyst from its subsidiary’s FDA approval.
? FDA Approval Triggers Rally
Biocon’s subsidiary received U.S. FDA clearance for Kristy, a biosimilar version of insulin aspart—a rapid‑acting human insulin. Kristy, already available in the EU and Canada since 2022, is now the only interchangeable biosimilar to Novolog in the U.S., which boosted investor sentiment sharply. 1
? Stock Performance & Technical Snapshot
The share price surged from about ₹396 to ₹406 over three sessions, marking a new high. It remains among top performers on the Nifty Midcap 150 index. ➕ Volume hit over 6.2 million shares with a price band between ₹396–₹406. 2
? Financial Growth Trajectory
- Annual revenue: Rose steadily from ₹7,106 cr (2021) to ₹15,262 cr (FY25), a 3.4% gain in FY25. 3
- Net profit: Climbed from ₹1,382 cr to ₹1,429 cr in FY25 (+3.4%). 4
- EPS: Grew from ₹6.24 in 2021 to ₹8.46 in 2025. 5
- Book value per share: Increased from ₹70.09 to ₹180.28. 6
- Debt-to-equity ratio: Rose from 0.47 to 0.82 over four years. 7
? Quarterly Trends & Dividend Info
In Q4 FY25, revenue reached ₹4,417 cr—its highest quarterly result. Biocon also declared a final dividend of ₹0.50 per share (10%), effective July 4, 2025. 8
? Analyst Insights
Moneycontrol’s analysis flags a bullish pattern: the FDA approval of Kristy, which contributed nearly US $1.9 billion in U.S. insulin sales (2024), is seen as a major growth engine. Biocon’s upgrade signals strong medium-term upside for investors. 9
? Trivia & Quiz Corner
- What catalyst triggered the stock’s rally? FDA approval of Kristy.
- Highest recent share price? ₹406.
- Annual revenue in FY25? ₹15,261.70 cr.
- Final dividend declared? ₹0.50 per share.
- Book value per share in 2025? ₹180.28.
✅ Final Takeaway
Biocon’s share surge underscores the power of regulatory approvals in the biotech sector. With solid financials, attractive valuation metrics, and a blockbuster biosimilar in the U.S., investors are watching closely for sustained growth.
Source: Moneycontrol